BSE filing, NSE: VENMAX. Summary written from the filing by ALFA Finder's alert engine.
Venmax Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹13.39
- Market cap
- ₹11.76 Cr
- Revenue (annual)
- ₹8.02 Cr
- Net profit (annual)
- ₹0.25 Cr
- P/E (TTM)
- 42.0×Sector 45.9×
- Promoter holding
- 10.46%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venmax Drugs & Pharmaceuticals Ltd
All →Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs' shareholders met on 24 October 2026 under an NCLT order to approve an amalgamation with Hatri Pharma. Voting results await the scrutinizer's report.
Venmax Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the quarter ended September 30, 2026.
Venmax Drugs & Pharmaceuticals Annual General Meeting
Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.
Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.
Venmax Drugs & Pharmaceuticals Acquisition
NCLT Hyderabad directed Venmax to convene a shareholder meeting on 24 Oct 2026 for the amalgamation of Hatri Pharma into Venmax. The order also dispensed with meetings of Hatri Pharma's shareholders and creditors.
Venmax Drugs & Pharmaceuticals Annual Report
Venmax Drugs and Pharmaceuticals Limited has submitted its Annual Report for the Financial Year 2025-26, including the Notice for its 37th Annual General Meeting.
Other board meeting date announcements
All →Sanco Trans Board Meeting Date
Sanco Trans scheduled a November 12, 2026 board meeting to consider unaudited half-year results for September 2026. The trading window is closed until November 16, 2026.
Auro Laboratories Board Meeting Date
Auro Laboratories scheduled a November 13, 2026 board meeting to approve unaudited September quarter results. The trading window stays closed until 48 hours after the meeting.
Abril Paper Tech Board Meeting Date
Abril Paper Tech will hold a board meeting on 5 November 2026 to consider unaudited half-year results for September 2026. The trading window stays closed until 48 hours after the results are released.
SJP Ultrasonics Board Meeting Date
SJP Ultrasonics intimated BSE of a board meeting on November 5, 2026 to approve unaudited half-year results and limited review report. Trading window reopens November 7, 2026, 48 hours after results.
Ambica Agarbathies & Aroma Industries Board Meeting Date
Ambica Agarbathies & Aroma Industries has notified a board meeting on 5 November 2026 to consider unaudited financial results for the quarter and half year ended 30 September 2026. The filing is an advance intimation, with the results not yet approved.
Minal Industries Board Meeting Date
Minal Industries scheduled a board meeting on November 05, 2026 to approve unaudited standalone and consolidated results for Q2 and H1 ended September 30, 2026. The trading window stays closed until 48 hours after the results declaration.